Hi-Q Marine Biotech Wins Esteemed NutraIngredients-Asia Award 2023: The 'Oscar' of Nutritional Ingredients Industry

(中央社訊息服務20231005 13:35:54)Hi-Q Marine Biotech has achieved a significant milestone by securing the esteemed NutraIngredients-Asia Award 2023. This highly regarded accolade, often referred to as the "Oscar" in the global nutritional ingredient industry, was announced during the opening evening of the Growth Asia Summit, Singapore. This three-day event has brought together 250 senior industry leaders, converging to explore the foremost growth opportunities in the food, nutrition, and beverage sectors.

This year marked a remarkable surge in participation, with a record-breaking 180 submissions encompassing a wide array of products, ingredients, and initiatives from across the region. The high standards and sheer number of entries made the judging process notably challenging.

Hi-Q has been awarded the Nutrition Research Project Specialty Award for our project titled " Exploring the Adjunct Therapeutic Potential of OliFuco^® Oligo Fucoidan in Supplemental Intervention for Cancer Cachexia: Enhancing Treatment Outcomes and Improving Quality of Life". This award-winning research project not only represents Hi-Q's outstanding contributions to the global nutritional ingredient industry but also provides cancer patients worldwide with more supplemental treatment options.

Hi-Q’s research project addresses a pressing consumer demand and significant public health concern in the field of cancer care and nutrition. Ensuring access to nutrition resources is fundamental to quality cancer care. Early and proactive nutrition care is associated with improved outcomes as patients progress through their cancer journey to cure or palliation. There is a critical need to improve the quality of life and treatment outcomes for cancer patients, particularly regarding the management of cancer cachexia and other side effects. Cancer cachexia poses a major challenge in healthcare as it leads to severe weight loss, muscle atrophy, fatigue, and inflammation, negatively impacting patients' well-being and treatment response. The lack of effective interventions and limited access to appropriate nutrition resources further compound the problem. Hi-Q’s research aims to address these challenges by investigating the potential of functional ingredient as an adjunctive therapy for patients experiencing cachexia and management of chronic diseases that contribute to cancer risk. By providing a targeted nutritional or supplemental intervention, Hi-Q hopes to fill the existing gap in cancer care.

Furthermore, Hi-Q’s dedication to scientific excellence is evident through the publication of over 50 scientific papers, with a significant focus on cancer and the immune system. For more than a decade, Hi-Q actively collaborates with leading research institutions, hospitals, and universities to advance cancer nutrition research and develop innovative solutions. This collaborative approach allows them to tap into a vast network of experts, gaining valuable insights and fostering groundbreaking advancements in the field. Moreover, Hi-Q continues to actively pursue further research and development endeavors. Hi-Q's win at the NutraIngredients-Asia Award not only reaffirms its remarkable contributions to the global nutritional ingredient industry but also reflects the company's commitment to advancing health and well-being.